XML 63 R48.htm IDEA: XBRL DOCUMENT
v3.6.0.2

BUSINESS SEGMENT INFORMATION (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2016
Segment Reporting [Abstract] |
Schedule of Segment Reporting Information, by Segment | The following table is a summary of segment information for the years ended December 31, 2016, 2015 and 2014. Segment asset information is not presented since it is not used by the chief operating decision maker at the operating segment level. Operating earnings (loss) of each segment represents net revenues less directly identifiable expenses to arrive at operating income (loss) for the segment. General corporate activities included in the table below are comprised of general management and administrative corporate expenses, amortization and impairment of intangibles assets, other operating income and expenses net of certain general corporate activity costs that are allocated to the DIS and DS businesses, and the gains on disposition of businesses associated with the dispositions of Focus Diagnostics and Clinical Trials (see Note 6) . The accounting policies of the segments are the same as those of the Company as set forth in Note 2.
| 2016 |  | 2015 |  | 2014
Net revenues: |  |  |  |  |  |  |
DIS business | $ | 7,138 |  |  | $ | 6,965 |  |  | $ | 6,873 |
All other operating segments | 377 |  |  | 528 |  |  | 562 |
Total net revenues | $ | 7,515 |  |  | $ | 7,493 |  |  | $ | 7,435 |
Operating earnings (loss): |  |  |  |  |  |  |
DIS business | $ | 1,244 |  |  | $ | 1,118 |  |  | $ | 1,068 |
All other operating segments | 64 |  |  | 110 |  |  | 94 |
General corporate activities | (31 | ) |  | 171 |  |  | (179 | )
Total operating income | 1,277 |  |  | 1,399 |  |  | 983 |
Non-operating expenses, net | (191 | ) |  | (296 | ) |  | (160 | )
Income from continuing operations before income taxes and equity in earnings of equity method investees | 1,086 |  |  | 1,103 |  |  | 823 |
Income tax expense | (429 | ) |  | (373 | ) |  | (262 | )
Equity in earnings of equity method investees, net of taxes | 39 |  |  | 23 |  |  | 26 |
Income from continuing operations | 696 |  |  | 753 |  |  | 587 |
Income from discontinued operations, net of taxes | — |  |  | — |  |  | 5 |
Net income | 696 |  |  | 753 |  |  | 592 |
Less: Net income attributable to noncontrolling interests | 51 |  |  | 44 |  |  | 36 |
Net income attributable to Quest Diagnostics | $ | 645 |  |  | $ | 709 |  |  | $ | 556 |
Depreciation and amortization expense for the years ended December 31, 2016, 2015 and 2014 were as follows:
| 2016 |  | 2015 |  | 2014
DIS business | $ | 170 |  |  | $ | 212 |  |  | $ | 206 |
All other operating segments | 6 |  |  | 10 |  |  | 13 |
General corporate | 73 |  |  | 82 |  |  | 95 |
Total depreciation and amortization | $ | 249 |  |  | $ | 304 |  |  | $ | 314 |
Capital expenditures for the years ended December 31, 2016, 2015 and 2014 were as follows:
| 2016 |  | 2015 |  | 2014
DIS business | $ | 264 |  |  | $ | 243 |  |  | $ | 283 |
All other operating segments | 21 |  |  | 16 |  |  | 17 |
General corporate | 8 |  |  | 4 |  |  | 8 |
Total capital expenditures | $ | 293 |  |  | $ | 263 |  |  | $ | 308 |
Net revenues by major service for the years ended December 31, 2016, 2015 and 2014 were as follows:
| 2016 |  | 2015 |  | 2014
Routine clinical testing services | $ | 4,179 |  |  | $ | 4,078 |  |  | $ | 4,066 |
Gene-based and esoteric (including advanced diagnostics) testing services | 2,335 |  |  | 2,256 |  |  | 2,158 |
Anatomic pathology testing services | 624 |  |  | 631 |  |  | 649 |
All other | 377 |  |  | 528 |  |  | 562 |
Total net revenues | $ | 7,515 |  |  | $ | 7,493 |  |  | $ | 7,435 |

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8813-108599 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8721-108599 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8736-108599 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration